Recently, patients diagnosed with recurrent and/or metastatic non-small cell lung cancer (NSCLC) were shown to significantly benefit from combination therapy with atezolizumab, an anti-PD-L1-antibody, and tiragolumab, an antibody blocking TIGIT (T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains) signaling [11]. Here, CD274 is linked to non-small cell lung carcinoma.